KPIs & Operating Metrics(New)
Growth Metrics

Bristol Myers Squibb (BMY) EBIT Margin (2016 - 2026)

Bristol Myers Squibb has reported EBIT Margin over the past 18 years, most recently at 1.58% for Q1 2026.

  • Quarterly EBIT Margin fell 103.0% to 1.58% in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 9.75% through Mar 2026, up 696.0% year-over-year, with the annual reading at 9.56% for FY2025, 3671.0% up from the prior year.
  • EBIT Margin was 1.58% for Q1 2026 at Bristol Myers Squibb, up from 21.01% in the prior quarter.
  • Over five years, EBIT Margin peaked at 1.8% in Q1 2023 and troughed at 121.77% in Q1 2024.
  • The 5-year median for EBIT Margin is 6.73% (2022), against an average of 15.65%.
  • Year-over-year, EBIT Margin plummeted -12357bps in 2024 and then surged 12122bps in 2025.
  • A 5-year view of EBIT Margin shows it stood at 6.44% in 2022, then crashed by -45bps to 9.33% in 2023, then tumbled by -303bps to 37.57% in 2024, then surged by 44bps to 21.01% in 2025, then soared by 92bps to 1.58% in 2026.
  • Per Business Quant, the three most recent readings for BMY's EBIT Margin are 1.58% (Q1 2026), 21.01% (Q4 2025), and 2.63% (Q3 2025).